Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

260
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
260
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

1.5K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
1.5K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mobile App-Based Interactive Care Plan for Migraine: Survey Study of Usability and Improvement Opportunities.

JMIR formative research·2025
Same author

Causes of Intracranial Hypotension: Spontaneous, Traumatic, and Iatrogenic Cerebrospinal Fluid Leaks.

Neuroimaging clinics of North America·2024
Same author

Improving Neurology Inpatient Fall Rate: Effect of a Collaborative Interdisciplinary Quality Improvement Initiative.

Mayo Clinic proceedings. Innovations, quality & outcomes·2023
Same author

Current Understanding of the Pathophysiology and Approach to Tension-Type Headache.

Current neurology and neuroscience reports·2021
Same author

Interstitial amyloidosis in sporadic inclusion body myositis.

Muscle & nerve·2021
Same author

First Bite Syndrome: What Neurologists Need to Know.

Current pain and headache reports·2021
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
查看所有相关文章

相关实验视频

Updated: Jul 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

8.9K

这是一种5-HT1F激动剂.

Stephanie J Steel1

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, United States.

Handbook of clinical neurology
|February 2, 2024
PubMed
概括
此摘要是机器生成的。

选择性5-HT1F激动剂,如拉斯米迪坦,在没有血管收缩的情况下提供偏头痛缓解,使特定患者受益. 然而,中枢神经系统的副作用和驾驶限制可能会限制它们的使用.

关键词:
拉斯米迪坦是拉斯米迪坦的意思.偏头痛是一种偏头痛.救援疗法是一种救援疗法.血清激素激动剂 血清激素激动剂三胞胎腺节的三胞胎腺节.

更多相关视频

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

15.4K
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

13.8K

相关实验视频

Last Updated: Jul 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

8.9K
The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System
11:27

The Use of Pharmacological-challenge fMRI in Pre-clinical Research: Application to the 5-HT System

Published on: April 25, 2012

15.4K
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
14:55

Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI

Published on: April 18, 2011

13.8K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 神经学 神经学
  • 药用化学 医学化学

背景情况:

  • 血清素受体激应是一种已知的三片偏头痛药物的机制.
  • 选择性5-HT1F受体激动剂代表了一类较新的偏头痛治疗药物.
  • 在减少急性偏头痛症状方面,5-HT1F激动剂的确切作用机制仍在研究中.

研究的目的:

  • 审查选择性5-HT1F激动剂在治疗急性偏头痛发作中的临床疗效和效用.
  • 要强调拉斯米迪坦是这个类别中唯一批准的药物.
  • 讨论拉斯米迪坦的优点和局限性,特别是它缺乏血管收缩性质.

主要方法:

  • 审查现有的临床试验数据和对选择性5-HT1F激动剂的药理学研究.
  • 对拉斯米迪坦的作用机制和受体结合特征的分析.
  • 评估拉斯米迪坦的安全性,包括中枢神经系统的副作用和禁忌.

主要成果:

  • 选择性5-HT1F激动剂,以拉斯米迪坦为例,在治疗急性偏头痛方面表现出临床有效性.
  • 拉斯米迪坦的非血管收缩性为无法使用三剂的患者提供了替代方案.
  • 潜在的限制包括中枢神经系统的副作用和相关的8小时驾驶限制.

结论:

  • 选择性5-HT1F激动剂为急性偏头痛治疗提供了一个新的治疗选择.
  • 拉斯米迪坦的独特特征使其适合特定患者群体.
  • 为了获得最佳的临床应用,需要进一步考虑副作用和使用限制.